Bio-Techne Set to Announce Q3 Earnings on May 6
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 05 2026
0mins
Source: seekingalpha
- Earnings Announcement Schedule: Bio-Techne (TECH) is set to release its Q3 earnings on May 6 before market open, with consensus EPS estimate at $0.53, reflecting a 5.4% year-over-year decline, and revenue estimate at $316.06 million, indicating stability in the current economic environment.
- Historical Performance Review: Over the past two years, Bio-Techne has beaten EPS estimates 75% of the time and revenue estimates 63% of the time, demonstrating a degree of reliability and market confidence in its financial performance.
- Expectation Revision Dynamics: In the last three months, EPS estimates have seen one upward revision and eight downward revisions, while revenue estimates have also experienced one upward and eight downward revisions, reflecting analysts' cautious outlook on the company's future performance, which may impact investor confidence.
- Market Environment Impact: Amid disruptions in the Middle East, Bio-Techne is considered one of the oversold mid-cap healthcare stocks on Wall Street, indicating differing market perceptions of its future growth potential, which may present a buying opportunity for investors.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TECH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TECH
Wall Street analysts forecast TECH stock price to rise
9 Analyst Rating
6 Buy
3 Hold
0 Sell
Moderate Buy
Current: 47.370
Low
60.00
Averages
66.14
High
72.00
Current: 47.370
Low
60.00
Averages
66.14
High
72.00
About TECH
Bio-Techne Corporation develop, manufacture and sell life science reagents, instruments and services for the research, diagnostics and bioprocessing markets worldwide. The Company’s segments include Protein Sciences segment and Diagnostics and Spatial Biology segment. The Protein Sciences segment is a developer and manufacturer of purified proteins and reagent solutions, most notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents and T-Cell activation technologies. The Diagnostics and Spatial Biology segment develops and manufactures diagnostic products, including controls, calibrators, blood gas and clinical chemistry controls and other reagents for OEM and clinical customers. This segment also manufactures and sells fully automated multiomic spatial biology instrumentation and advanced tissue-based in-situ hybridization assays (ISH) for research and clinical use.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Bio-Techne Stock Down 17.4% Year-to-Date
- Analyst Ranking Overview: The ranking of 500 components is formed by averaging analyst opinions, reflecting market sentiment towards each component, indicating a lack of confidence in Bio-Techne among investors.
- Stock Performance Review: Year-to-date, Bio-Techne's stock has declined by approximately 17.4%, a significant drop that may impact investor confidence and lead to capital outflows.
- Market Reaction Analysis: The disparity between analyst opinions and market performance could result in increased volatility for Bio-Techne in future trading, necessitating close monitoring of market dynamics by investors.
- Overall Market Trend: Bio-Techne's performance contrasts with current market trends, suggesting that measures may be needed to restore investor confidence and improve stock performance.
See More
Comparison of TECH and PNC Stock Performance
- Stock Performance Comparison: TECH is currently trading down approximately 4.6%, while PNC is down about 0.2%, indicating differing performances that may affect investor confidence and decision-making.
- Market Sentiment Analysis: The significant decline in TECH's stock may reflect market concerns regarding its future growth potential, impacting shareholder investment strategies and decisions.
- PNC Stock Stability: Although PNC's stock has also seen a slight decline, its relatively stable performance may attract investors seeking lower-risk opportunities, thereby enhancing its market appeal.
- Investor Focus Shift: As market attention on both stocks increases, investors may reassess their portfolios to navigate current market dynamics and potential risks.
See More
Bio-Techne (TECH) Q4 2025 Earnings Transcript
See More
Bio-Techne (TECH) Q3 2026 Earnings Transcript
See More
Bio-Techne (TECH) Q1 2025 Earnings Transcript
See More
Bio-Techne Q3 2026 Earnings Call: Market Challenges and Growth Potential
- Financial Performance Overview: Bio-Techne reported total revenue of $311.4 million for Q3, reflecting a 2% year-over-year decline, with adjusted EPS at $0.53, indicating ongoing support from large pharmaceutical customers despite softness in emerging biotech spending.
- Market Dynamics Analysis: While the large pharma sector achieved double-digit growth for the sixth consecutive quarter, the emerging biotech market experienced a surprising decline in high single digits, as noted by CEO Kelderman, which unexpectedly pressured the company's performance.
- Strategic Adjustment Plan: In April, the company announced a strategic brand alignment, streamlining its portfolio from 10 brands to 3, aimed at enhancing operational efficiency and strengthening market competitiveness, which is expected to positively impact future revenue growth.
- Future Outlook and Challenges: Management anticipates flat organic growth in Q4, emphasizing the lag of 2 to 3 quarters between funding and spending in the biotech market, which may influence future growth trends.
See More
Bio-Techne Stock Down 17.4% Year-to-Date
- Analyst Ranking Overview: The ranking of 500 components is formed by averaging analyst opinions, reflecting market sentiment towards each component, indicating a lack of confidence in Bio-Techne among investors.
- Stock Performance Review: Year-to-date, Bio-Techne's stock has declined by approximately 17.4%, a significant drop that may impact investor confidence and lead to capital outflows.
- Market Reaction Analysis: The disparity between analyst opinions and market performance could result in increased volatility for Bio-Techne in future trading, necessitating close monitoring of market dynamics by investors.
- Overall Market Trend: Bio-Techne's performance contrasts with current market trends, suggesting that measures may be needed to restore investor confidence and improve stock performance.
See More
Comparison of TECH and PNC Stock Performance
- Stock Performance Comparison: TECH is currently trading down approximately 4.6%, while PNC is down about 0.2%, indicating differing performances that may affect investor confidence and decision-making.
- Market Sentiment Analysis: The significant decline in TECH's stock may reflect market concerns regarding its future growth potential, impacting shareholder investment strategies and decisions.
- PNC Stock Stability: Although PNC's stock has also seen a slight decline, its relatively stable performance may attract investors seeking lower-risk opportunities, thereby enhancing its market appeal.
- Investor Focus Shift: As market attention on both stocks increases, investors may reassess their portfolios to navigate current market dynamics and potential risks.
See More
Bio-Techne (TECH) Q4 2025 Earnings Transcript
See More
Bio-Techne (TECH) Q3 2026 Earnings Transcript
See More
Bio-Techne (TECH) Q1 2025 Earnings Transcript
See More
Bio-Techne Q3 2026 Earnings Call: Market Challenges and Growth Potential
- Financial Performance Overview: Bio-Techne reported total revenue of $311.4 million for Q3, reflecting a 2% year-over-year decline, with adjusted EPS at $0.53, indicating ongoing support from large pharmaceutical customers despite softness in emerging biotech spending.
- Market Dynamics Analysis: While the large pharma sector achieved double-digit growth for the sixth consecutive quarter, the emerging biotech market experienced a surprising decline in high single digits, as noted by CEO Kelderman, which unexpectedly pressured the company's performance.
- Strategic Adjustment Plan: In April, the company announced a strategic brand alignment, streamlining its portfolio from 10 brands to 3, aimed at enhancing operational efficiency and strengthening market competitiveness, which is expected to positively impact future revenue growth.
- Future Outlook and Challenges: Management anticipates flat organic growth in Q4, emphasizing the lag of 2 to 3 quarters between funding and spending in the biotech market, which may influence future growth trends.
See More
